ledipasvir/sofosbuvir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 54 Diseases   8 Trials   8 Trials   2662 News 


«12345678910111213...2324»
  • ||||||||||  ombitasvir (ABT-267) / AbbVie, Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
    Journal:  The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia. (Pubmed Central) -  Nov 18, 2022   
    All patients with HCV treated with either ledipasvir plus sofosbuvir (LDS/SOF) ± ribavarin (RBV) or ombitasvir-paritaprevir-ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± RBV were included...Medications were well tolerated with minimal side effects, including vomiting, nausea, and weakness. DAAs regimens are associated with high rates of SVR12 and are well tolerated with a good safety profile in Saudi HCV-infected patients.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Reimbursement, Journal, Medicaid:  Uptake of Hepatitis C Virus Treatment in a Multi-State Medicaid Population, 2013 - 2017. (Pubmed Central) -  Nov 15, 2022   
    LDV/SOF approval and lifting PA requirements led to an increase in uptake followed by flat monthly utilization. Cumulative uptake was higher in plans with few/no PA requirements relative to those with three requirements through mid-2016.
  • ||||||||||  Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
    Trial completion:  CTN289: HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (clinicaltrials.gov) -  Nov 14, 2022   
    P3,  N=25, Completed, 
    Cumulative uptake was higher in plans with few/no PA requirements relative to those with three requirements through mid-2016. Unknown status --> Completed
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Trial primary completion date:  CHROME: Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication (clinicaltrials.gov) -  Nov 1, 2022   
    P4,  N=90, Recruiting, 
    Moreover, the analytical instrumentation and methods used in determination of these DAADs will be illustrated in tabulated forms. Trial primary completion date: Jul 2022 --> Dec 2022
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    ACTIVE DRUG USE IS NOT ASSOCIATED WITH TREATMENT FAILURE AMONG PWID PATIENTS WITH VARIABLE ADHERENCE TO HCV TREATMENT () -  Oct 23, 2022 - Abstract #AASLD2022AASLD_822;    
    Information collected included HCV genotype, treatment regimen, use of opiate substitution therapy (OST; i.e. buprenorphine/naltrexone, methadone), active drug use (patient-reported or positive urine toxicology), adherence and SVR...The most commonly prescribed DAA regimens were: sofosbuvir-velpatasvir (N=33), sofosbuvir-ledipasvir (13 patients; 9 for 12 weeks and 4 for 8 weeks), glecaprevir-pibrentasvir for 8 weeks (N=39), elbasvir-grazoprevir (N=8) and other (N=18)... Among PWID patients who have variable adherence to HCV therapy, active drug use and prescription opioid use during treatment were not associated with treatment failure.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    YOUNGER AGE IS ASSOCIATED WITH LOWER TREATMENT ADHERENCE AMONG PWID TREATED FOR CHRONIC HCV INFECTION () -  Oct 23, 2022 - Abstract #AASLD2022AASLD_821;    
    Younger age is associated with lower rates of adherence among PWID treated at the La Bodega Clinic. Further work is needed to better engage younger patients in HCV therapy.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    CASCADE OF CARE FOR CHRONIC HCV INFECTION IN A LARGE HOMELESS METROPOLITAN POPULATION () -  Oct 23, 2022 - Abstract #AASLD2022AASLD_797;    
    Significant improvements in testing and treating in sites where PEH access healthcare has improved the linkage to care, such that the outcomes in this population are equivalent to other populations. Flexibility in treating strategies and maximising opportunities for engagement are key to successful outcomes.
  • ||||||||||  Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    HEPATITIS C VIRUS PREVALENCE AND OUTCOMES AMONG PREGNANT WOMEN WHO INJECT DRUGS () -  Oct 23, 2022 - Abstract #AASLD2022AASLD_766;    
    More research is needed regarding treatment among pregnant women. Treatment in the 3rd trimester is feasible thus preventing vertical transmission.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    RETREATMENT AND RESISTANCE-ASSOCIATED SUBSTITUTIONS IN HEPATITIS C PATIENTS WHO FAILED DIRECT-ACTING ANTIVIRAL THERAPY IN KOREA () -  Oct 23, 2022 - Abstract #AASLD2022AASLD_763;    
    Retreatment of patients with DAA failure is highly successful although the retreatment rate is not satisfactory probably due to limited access to effective DAA in Korea. Further studies for more patients with DAA failure are warranted to clarify the outcome of retreatment in association with RAS.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Harvoni = hard bony (Twitter) -  Sep 29, 2022   
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Review, Journal:  Treatment of hepatitis C in children and adolescents: how far have we reached? (Pubmed Central) -  Sep 23, 2022   
    These drugs represent a safe and affordable treatment for COVID-19. The literature on different DAA regimens for use in children shows that these regimens have higher cure rates with minimal side effects and shorter duration of therapy.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Observational data, Journal:  High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus. (Pubmed Central) -  Sep 14, 2022   
    In conclusion, we could not find any differences in the incidence of HCC after the HCV eradication between the two therapeutic regimens, suggesting no enhancement of HCC development by DAA. Eight weeks of DAA therapy is highly effective and safe in HCV-infected patients with different types of malignancies and may grant access to investigational cancer therapy, broadening treatment options.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Journal, HEOR:  Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in VA Patients with Hepatitis C Virus Infection. (Pubmed Central) -  Sep 10, 2022   
    The mean differences in improvement on the PCL were smaller between GLE/PIB and SOF/VEL (3.0; 95% CI -6.3, 12.2) and between SOF/VEL and LDV/SOF (4.4; 95% CI -2.4, 11.2). While almost all patients were cured of HCV (92.5%) regardless of the agent received, PTSD outcomes were superior for those receiving GLE/PIB compared to those receiving LDV/SOF, indicating GLE/PIB may merit further investigation as a potential PTSD treatment.
  • ||||||||||  Cryoglobulinemic Vasculitis After 6 Years of Sustained Virologic Response in a Post-Liver Transplant Patient (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_3514;    
    MRI orbits revealed lacrimal gland adenititis treated with topical medications including erythromycin and systemic acetazolamide...Notably, she was treated with ledipasvir/sofosbuvir and ribavirin which was completed 7/2015 with SVR achieved 12/2015...She was treated with pulse dose solumedrol and plasmapheresis...Her creatinine returned to baseline and she was started on prednisone 60mg daily...Moreover, multiple modalities of diagnosis may need to be pursued if initial biopsies are not conclusive to establish effective treatment plans. Overall, CV should remain on the differential in patients with a treated HCV and SVR.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy (clinicaltrials.gov) -  Aug 23, 2022   
    P1/2,  N=24, Recruiting, 
    Further research with larger groups of patients is needed to confirm our findings. Unknown status --> Recruiting | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Mar 2021 --> Mar 2023
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Harvoni Treatment Porphyria Cutanea Tarda (clinicaltrials.gov) -  Aug 4, 2022   
    P2,  N=22, Completed, 
    EBR/GZR and LDV/SOF regimens had clinically equivalent and durable improvements in HCV symptoms and functional well-being up to two years after SVR. Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Mar 2022 | Trial primary completion date: Sep 2022 --> Mar 2022
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Journal:  Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study. (Pubmed Central) -  Jul 17, 2022   
    In conclusion, this case series study found that sofosbuvir-based therapy for pregnant women and infant with severe CHC is safe and effective. The data may fill the gap and provide evidence of the use of sofosbuvir-based therapy as a reference when similar severe CHC situations are encountered during clinical practice.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Vemlidy (tenofovir alafenamide) / Gilead
    Retrospective data, Journal:  Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. (Pubmed Central) -  Jun 22, 2022   
    SOF-based regimens had 2.72-fold higher relative risk (RR) causing 10% elevation of TC (95% CI 1.84-4.02, p < 0.001) and 2.04-fold higher RR causing 10% elevation of LDL-C (95% CI 1.39-3.01, p < 0.001) than non-SOF-based DAAs. SOF-based DAAs were associated with significantly larger amplitude of increases in TC and LDL-C than non-SOF-based DAAs during the initial 4 weeks of treatment, but the increases were not sustained to SVR12.